Member Info for Rokerpark68

Great stuff Shiraz - thank you.

Hi Shiraz
I hope all is well with you.
I wanted to ask you about GC's reference to PRVB at the end of the session and why he thought it was so interesting in the context of TILS's science.
What did you make of it please?
Thanks
Roker

Yes I was pleased GC was on the call too - Kunwar is enthusiastic but is a poor presenter and should only be used sparingly. When he is needed he should be carefully scripted so he is more precise. Just sounds like he is flannelling sometimes.

Sorry -

based on whatever the success was (last line)

Can't type today.

Hello robortsmith

Yes, they did say they were funded for the current two-year development programme, but GC was keen to add that if they had some success in their current programme which meant additional expenditure was required for further trials then they would raise again if necessary, but that this should be at a much improved valuation based whatever the success was.

Yes, time is very very tight for the AIM to Main move by the year end.

Jack - yes I agree as you can see from my post just after yours on Main listing timing.

I think going on to the Main market could (and should) lead to upgrades in other areas which are badly needed:

1. Bigger hitting financial advisers and brokers.
2. Better and wider broker coverage.
3. Appointment of an experienced COO to allow Kunwar to focus on science and trials and GC on strategy and negotiations.
4. Appointment of a dedicated PR/IR professional who can handle calls like yesterday in a concise way with consistent messaging.

I think they really do need to deliver on the move to the Main market before the year end. I can probably forgive slippage on drug trials as long as they are heading in the right direction, but the board really should stick to a timeline for something which is a well-worn process such as moving from AIM to Main.

I think it will make TILS more investable to some of the larger funds and will raise its profile. So they need to execute as promised.

Hi Oldapache

I have put my own CV in for the Sunderland job. I reckon a retired fund manager could do better than Phil Parkinson.

Absolutely, PRVB could be an NDA candidate. But I don't know.

sorry "thing" rather than "think" in line 3.

Morning BMO3,

I listened to the whole call last night.

The most interesting think I took away was GC's very strong signposting to Provention Bio (PRVB) in the US which, according to that company's website, "is developing and bringing medicines to market that have the potential to intercept and prevent autoimmune diseases". Unfortunately my grasp of the science around TILS is insufficient to really understand why the recent success of PRVB's work is apparently so supportive of parts of TILS's therapeutic portfolio. It was the first time I had heard PRVB mentioned in the context of TILS. Could you, or anyone else on this BB with science knowledge, throw more light on this? PRVB obviously had a breakthrough in the summer of 2019 which led to a major re-rating of its stock. GC made quite a point of this out of nowhere.

Any thoughts please?

Good to see the Accustem website is "under construction".

Can't be long before we get the Admission prospectus promised in the Accustem Demerger Shareholder CIrcular.

Glad to be of service.

I suspect that they might also have outgrown their financial advisers and brokers. If they really are set for fast growth or some major M&A, I'd like to see them engage some larger firms with better investor reach/deeper resources. Perhaps this will happen when the move from AIM occurs.

Sorry, should be "too thinly" in line three.

Hi Greend100

You summed-up my own views about TILS in your post - agree totally with your thinking.

I think your point about the board being spread to thinly is a very good one. They have been in overload for some time now. I wonder if they should be adding more operational and financial experience to allow GC and Kunwar to focus more on strategy and science respectively.

Anyway, this is an interesting ride and I'm sure there will be many twists and turns over the coming months. I only have five what I call high risk/high return investments and this is one of them. I only expect probably two of them to come off and my analysis still makes be think this is likely to be one of the successes.

All the short-term price angst will seem pretty meaningless if some of the product development really comes good. Most important for me is that they have the finance to get the pipeline well-advanced.

As for Accustem, it's going to be fascinating seeing how the listing is handled and executed. Can't wait!

Cheers

Hi smokieUK

Yes they would need to need to explain any delay to the market.

Getting corporate finance transactions over the line always gets hard as the Christmas holiday approaches (assuming there is anything resembling Christmas this year), so I hope they are well advanced.

With regard to finding out more about how Accustem is going to be valued and listed, this is extracted from page 27 of the Demerger Shareholder Circular, which is on the TILS website in the Rule 26 tab of the Investor section:

"8. Will I receive a prospectus relating to the shares that I am being issued in
Accustem?

A prospectus in relation to the Accustem Shares will be posted to Tiziana's website and will
also be available via Accustem's website www.accustem.com and via Tiziana’s website
www.tizianalifesciences.com.

Once approved and published, the prospectus will also be capable of being viewed online on
the National Storage Mechanism’s website or at the following places during normal business
hours on any weekday (Saturdays, Sundays and public holidays excepted) until Accustem
Admission:
• the registered office of Tiziana at 3
rd Floor, 11-12 St James's Square, London SW1Y 4LB;
and
• the offices of Orrick, Herrington & Sutcliffe (UK) LLP, 107 Cheapside, London EC2V ."

The Accustem Admission is defined on page 4 as follows:

"Accustem Admission the proposed applications for the admission of Accustem
Shares to the standard segment of the official list of the FCA
and to trading on the London Stock Exchange."

The Admission is planned to occur "during Q4", so they need to get a move on.

Just about everything currently known about Accustem is contained in the Shareholder Circular.

There are no details on valuation or how the Admission will work.

Morning,
I have been off the board the last few weeks, during which the SP has fallen significantly, all the way down to where I first purchased back in the spring and below where I added in the summer.

As I have said before I don't really let the short-term price movements bother me - there is little a PI can do about them.

What I do think is that the investment case is stronger than when I first invested. For example, the Accustem demerger has occurred, although there is still some final execution risk in relation to getting the company listed. As for Accustem's value, no certainty there, but it could be interesting.

The key change is that the company has the funding to develop its interesting therapeutic portfolio, which it did not have to anything like the same extent prior to the $57 million fund-raising.

So I'm holding tight waiting for the positive news flow which will hopefully emerge over the coming months and beyond.
We'll see. TILS is volatile and like all pre-revenue stocks comes with major execution risk, but then it's sized accordingly in my portfolios.

GLA

Hi Charlie Hurley
Sorry for the late reply. Been to town for a bit of shopping.
I'm sorry, I rarely have a clue where share prices are going in the short term, and TILS is no exception. In fact it's almost impossible to call TILS right as there are so many things going on behind the scenes.
I recommend going in to a dark room, putting a cold flannel over your forehead and then watching a DVD of the 1973 Sunderland v Leeds FA Cup final.
TILS is volatile because it is a pre- revenue company with a small free float. It will either be successful with some of its portfolio and we'll make some money, or it won't and we won't.
Just don't bet the ranch on this sort of stuff!
Que sera sera.
I am still a LTH.